Enhanced magnetic resonance imaging in multiple sclerosis

Multiple Sclerosis

Volumn 6, Issue 5, 2000, Pages 320-326

  Filippi, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Gd enhancement; MRI; MS; Treatment trials

Indexed keywords

BETA1A INTERFERON; GADOLINIUM;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTRAST SENSITIVITY; DISEASE COURSE; DOSE RESPONSE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; LESIONS AND DEFECTS; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; REVIEW; TISSUE INJURY;

EID: 0033755083     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245850000600505     Document Type: Review

References (86)

1. Multiple sclerosis: Gadolinium enhancement in MR imaging
2. Duration and selectivity of blood brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers
3. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology
4. Distinct patterns of multiple sclerosis indicates heterogeneity of pathogenesis
5. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis
6. Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis
7. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema
8. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis
9. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis
10. Disease activity in multiple sclerosis studied with weekly triple dose magnetic resonance imaging
11. Heterogeneity of blood-barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement
12. Patterns of disease activity in multiple sclerosis: Clinical and magnetic resonance imaging study
13. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history
14. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions
15. Magnetic resonance imaging changes with recombinant human interferon beta-1a: A short term study in relapsing-remitting multiple sclerosis
16. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis
17. Gadolinium enhanced MRI disease activity in relapsing-remitting multiple sclerosis
18. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability/impairment in multiple sclerosis: A metaanalysis
19. A longitudinal study of brain atrophy in relapsing multiple sclerosis
20. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
21. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
22. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis
23. Magnetic resonance imaging in the diagnosis of multiple sclerosis: A prospective study of comparison with clinical evaluation, evoked potential, oligoclonal banding, and CT
24. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis
25. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study
26. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis
27. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
28. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination
29. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
30. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs
31. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): Implications for phase II therapeutic trials
32. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis
33. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis
34. Exploratory treatment trials in multiple sclerosis using MRI: Sample size calculations for relapsing remitting and secondary progressive subgroups using placebo controlled parallel groups
35. Statistical power of MRI monitored trials in multiple sclerosis: New data and comparison with previous results
36. Improving intraobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis
37. Inter-rater variability in reporting enhancing lesions on standard and triple dose gadolinium scans in patients with multiple sclerosis
38. The role of magnetic resonance techniques in understanding and managing multiple sclerosis
39. Effect of interferon β-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a european multicenter, randomized, double-blind, placebo-controlled trial
40. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis
41. Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis
42. Sensitivity of contrast enhanced MRI in multiple sclerosis: Effects of gadolinium dose, magnetization transfer contrast and delayed imaging
43. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS
44. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: Implications for clinical trials
45. A high-resolution three-dimensional gradient echo sequence improves the detection of disease activity in multiple sclerosis
46. Single dose gadolinium with magnetization transfer contrast versus triple dose gadolinium in detecting enhancing multiple sclerosis lesions
47. Multiple sclerosis lesions: Relationship between MR enhancement pattern and magnetization transfer effect
48. Magnetization transfer effect in MR-detected multiple sclerosis lesions: Comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images
49. Improved detection of enhancing and non-enhancing lesions of multiple sclerosis with magnetization transfer
50. Sensitivity of enhanced MR in multiple sclerosis: Effects of contrast doses and magnetization transfer contrast
51. Quantitative assessment of magnetic resonance imaging lesion load in multiple sclerosis
52. Evidence of widespread subtle blood-brain barrier dysfunction associated with progressive MS
53. Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology
54. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients
55. Magnetization transfer ratios of contrast-enhancing and non enhancing lesions in multiple sclerosis
56. Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability
57. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis
58. A quantitative study of water diffusion in MS lesions and NAWM using echo-planar imaging
59. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
60. Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR
61. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis
62. A serial study of new MS lesions and the white matter from which they arise
63. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions
64. Magnetization transfer ratios in MS lesions enhancing after different doses of gadolinium
65. Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis
66. Magnetization transfer ratio changes in a symptomatic lesion of a patient at presentation with possible multiple sclerosis
67. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies
68. Long term changes of MT-derived measures from patients with relapsing-remitting and secondary-progressive multiple sclerosis
69. Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging
70. Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement
71. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
72. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis. Relation to inflammatory activity
73. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads
74. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
75. The effect of cladribine on T1 'black hole' changes in progressive MS
76. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
77. Interferon beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis
78. A longitudinal study of magnetization transfer in multiple sclerosis
79. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
80. A weekly magnetization transfer and diffusion weighted imaging study of multiple sclerosis lesions and NAWM
81. Normal-appearing white matter changes in multiple sclerosis: The contribution of magnetic resonance techniques
82. Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents
83. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance
84. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging
85. Multiple sclerosis: Interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images
86. Activity revealed in MRI of multiple sclerosis without contrast agent. A preliminary report